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Background
Amiodarone is a class III antiarrhythmic drug
(Vaughn-Williams classification) indicated for the
treatment of arrhythmias that works by increasing
the duration and refractory period of the cardiac
action potential prolonging the QT interval.
Officially approved for refractory ventricular
arrhythmias, it is frequently used for atrial
fibrillation and supraventricular tachycardias[1].
However, it carries significant side effects including
pulmonary fibrosis, epithelial keratopathy, thyroid
toxicity and hepatotoxicity. The incidence and
prevalence of serious adverse effects from
amiodarone therapy are as high as 15% within the
first year of use and up to 50% for long-term drug
therapy [2]. Monitoring for the development of
such complications is paramount.
The North American Society for Pacing and
Electrophysiology recommends baseline screening
tests for early detection and mitigation of
amiodarone adverse reactions.[3] These include:
- Evaluation of thyroid and liver function
tests prior to initiation of therapy and
then again every 6 months
- Baseline chest x ray and PFTs with
DLCO and then again yearly
- Ophthalmologic exam in the setting of
any visual disturbance at any time of the
therapy [4].
The purpose of this study was to determine
baseline adherence to amiodarone screening
guidelines and t.
Methods
EPIC was initially queried for patients initiated on
amiodarone both inpatient and outpatient from
April 2017 until October 2019. These patients were
then analyzed to determine compliance with
screening guidelines for complications of
amiodarone therapy. Following baseline
assessment of guideline adherence, we will then
design an EPIC tool to alert providers to
amiodarone screening recommendations for their
particular patient. We will then re-assess
compliance with screening guidelines.
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Conclusions
Amiodarone is a medication with significant side
effects, and adherence to recommendations to
screen for development of complications is
paramount. We intend to demonstrate that with the
aid of a clinical tool in EPIC provider compliance
with the recommended guidelines can be improved.
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